Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoZenge ABFRA:8LY +2.64%26 EPS without NRI is €-0.17 as of Mar. 2026. GuruFocus rates FRA:8LY with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,160 Biotechnology companies, OncoZenge AB ranks better than 52.67% on this metric.
OncoZenge AB's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was €-0.05.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.17.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for OncoZenge AB's EPS without NRI or its related term are showing as below:
FRA:8LY'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -150 Med: -30.6 Max: 18.4
Current: 18.4
FRA:8LY's 3-Year EPS without NRI Growth Rate is ranked better than 52.67% of 1160
companies
in the Biotechnology industry
Industry Median: 16.2
vs FRA:8LY: 18.40
OncoZenge AB's EPS (Diluted) for the
three
months ended in Mar. 2026 was €-0.05.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.17.
OncoZenge AB's EPS (Basic) for the
three
months ended in Mar. 2026 was €-0.05.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.17.
OncoZenge AB (FRA:8LY) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
OncoZenge AB EPS without NRI Related Terms
OncoZenge AB EPS without NRI Historical Data
* Premium members only.
The historical data trend for OncoZenge AB's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8LY vs VRTX, REGN, RVMD: EPS without NRI Comparison
For the Biotechnology subindustry, OncoZenge AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoZenge AB PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoZenge AB's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where OncoZenge AB's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.17
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoZenge AB (FRA:8LY) has a EPS without NRI of €-0.17 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on OncoZenge AB and its competitors. According to the industry distribution chart, OncoZenge AB ranks #549 out of 1160 companies in the Biotechnology industry, placing it in the top 47.3%.
Is OncoZenge AB's EPS without NRI too high?
OncoZenge AB's current EPS without NRI is €-0.17. Based on the distribution chart, OncoZenge AB ranks #549 out of 1160 companies in the Biotechnology industry, which is above the industry midpoint. Overall, OncoZenge AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does OncoZenge AB's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoZenge AB ranks #549 out of 1160 companies for EPS without NRI. This puts OncoZenge AB in the upper half of its industry. The industry median EPS without NRI is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.20, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on OncoZenge AB and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoZenge AB's current EPS without NRI is €-0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoZenge AB stock overvalued right now?
OncoZenge AB (FRA:8LY) has a current EPS without NRI of €-0.17. The current EPS without NRI is €-0.17. OncoZenge AB's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For OncoZenge AB (FRA:8LY), the current EPS without NRI is €-0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
26GF Score
Get the complete analysis for FRA:8LY
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8LY has been successfully added to your 
